Lessons Learned From Characterizing Long COVID Among US Medicare Beneficiaries
Open Access
- 22 January 2025
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 34 (2) , e70101
Abstract
Purpose: To characterize long‐term effects of COVID‐19 among older adults (aged ≥ 65 years).Methods: This retrospective descriptive study utilized Medicare Fee‐for‐Service beneficiaries' claims to characterize post‐COVID condition diagnosis code usage, long COVID (defined as post‐COVID condition diagnoses made ≥ 28 days after an initial COVID‐19 diagnosis) incidence, patient demographics, and concurrent diagnoses.Results: During April 1, 2020 to May 21, 2022, 193 691 (0.6%) of 31 847 927 Medicare beneficiaries were diagnosed with post‐COVID conditions using ICD‐10‐CM diagnosis codes U09.9 and B94.8, regardless of prior COVID‐19 diagnosis. Post‐COVID condition diagnosis rate was higher among nursing home residents (18.7 per 1000 person‐years) than community‐dwelling beneficiaries (2.8). Among community‐dwelling beneficiaries with a post‐COVID condition diagnosis, 17.5% did not have any prior COVID‐19 diagnosis code U07.1 recorded. Among beneficiaries with COVID‐19 diagnosis, there were no significant sex, age, or race/ethnicity differences between those with post‐COVID conditions ≥ 28 days after COVID‐19 (i.e., long COVID) and those without post‐COVID conditions. Certain myopathies and interstitial pulmonary disease codes were disproportionately present concurrently with long COVID compared to COVID‐19.Conclusions: In this large study of 32 million Medicare beneficiaries, we found approximately 194 000 post‐COVID condition diagnoses. Post‐COVID condition diagnosis rate was higher among nursing home residents, highlighting the substantial burden of COVID‐19 in this vulnerable population. Community‐dwelling beneficiaries were less likely to seek medical care for COVID‐19 events than nursing home residents, which may suggest differences in COVID‐19 severity and respiratory disease detection between these populations. Long COVID risk after COVID‐19 infection may be similar across demographic groups.Keywords
All Related Versions
Funding Information
- Food and Drug Administration (02309‐075‐075‐013007)
This publication has 18 references indexed in Scilit:
- Myopathy as a cause of fatigue in long‐term post‐COVID‐19 symptoms: Evidence of skeletal muscle histopathologyEuropean Journal of Neurology, 2022
- How common is long COVID? Why studies give different answersNature, 2022
- Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 InfectionJAMA Network Open, 2021
- Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort studyThe Lancet Regional Health - Europe, 2021
- Sequelae in adults at 12 months after mild‐to‐moderate coronavirus disease 2019 (COVID‐19)International Forum of Allergy & Rhinology, 2021
- Is myopathy part of long-Covid?Clinical Neurophysiology, 2021
- Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care WorkersJAMA, 2021
- High-dimensional characterization of post-acute sequelae of COVID-19Nature, 2021
- Sequelae in Adults at 6 Months After COVID-19 InfectionJAMA Network Open, 2021
- Persistent Symptoms in Patients After Acute COVID-19JAMA, 2020